

Cyrus V Desouza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/794446/publications.pdf>

Version: 2024-02-01

53
papers

1,675
citations

361296

20
h-index

289141

40
g-index

53
all docs

53
docs citations

53
times ranked

2345
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypoglycemia, Diabetes, and Cardiovascular Events. <i>Diabetes Care</i> , 2010, 33, 1389-1394.	4.3	374
2	Association of Hypoglycemia and Cardiac Ischemia: A study based on continuous monitoring. <i>Diabetes Care</i> , 2003, 26, 1485-1489.	4.3	341
3	Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 515-527.	5.5	180
4	Role of Inflammation and Insulin Resistance in Endothelial Progenitor Cell Dysfunction. <i>Diabetes</i> , 2011, 60, 1286-1294.	0.3	61
5	A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. <i>Diabetes Care</i> , 2018, 41, 1926-1937.	4.3	49
6	Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 361-367.	21.5	39
7	Cardiometabolic Effects of a New Class of Antidiabetic Agents. <i>Clinical Therapeutics</i> , 2015, 37, 1178-1194.	1.1	39
8	Differential Effects of Peroxisome Proliferator Activator Receptor- α and β Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2003, 8, 297-305.	1.0	38
9	Effect of Behavioral Therapy With In-Clinic or Telephone Group Visits vs In-Clinic Individual Visits on Weight Loss Among Patients With Obesity in Rural Clinical Practice. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 363.	3.8	36
10	Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes?. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 519-525.	1.2	35
11	Nanoformulated copper/zinc superoxide dismutase reduces adipose inflammation in obesity. <i>Obesity</i> , 2016, 24, 148-156.	1.5	32
12	Lauric Acid versus Palmitic Acid: Effects on Adipose Tissue Inflammation, Insulin Resistance, and Non-Alcoholic Fatty Liver Disease in Obesity. <i>Biology</i> , 2020, 9, 346.	1.3	30
13	Glycated Albumin at 4 Weeks Correlates with A1C Levels at 12 Weeks and Reflects Short-Term Glucose Fluctuations. <i>Endocrine Practice</i> , 2015, 21, 1195-1203.	1.1	27
14	Altered Brain Dynamics in Patients With Type 1 Diabetes During Working Memory Processing. <i>Diabetes</i> , 2018, 67, 1140-1148.	0.3	27
15	Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 543-556.	1.8	24
16	Results of a Study Comparing Glycated Albumin to Other Glycemic Indices. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 677-687.	1.8	23
17	Protocol for the Rural Engagement in Primary Care for Optimizing Weight Reduction (RE-POWER) Trial: Comparing three obesity treatment models in rural primary care. <i>Contemporary Clinical Trials</i> , 2016, 47, 304-314.	0.8	22
18	Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e130-e138.	1.8	22

#	ARTICLE	IF	CITATIONS
19	Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2010, 3, CMED.S5372.	1.0	21
20	Driving Safety and Real-Time Glucose Monitoring in Insulin-Dependent Diabetes. <i>International Journal of Automotive Engineering</i> , 2019, 10, 34-40.	0.3	21
21	Effects of Salsalate Therapy on Recovery From Vascular Injury in Female Zucker Fatty Rats. <i>Diabetes</i> , 2010, 59, 3240-3246.	0.3	20
22	Inpatient Hypoglycemia: A Challenge That Must Be Addressed. <i>Current Diabetes Reports</i> , 2014, 14, 445.	1.7	20
23	Nanoformulated copper/zinc superoxide dismutase exerts differential effects on glucose vs lipid homeostasis depending on the diet composition possibly via altered AMPK signaling. <i>Translational Research</i> , 2017, 188, 10-26.	2.2	20
24	Neointimal hyperplasia and vascular endothelial growth factor expression are increased in normoglycemic, insulin resistant, obese fatty rats. <i>Atherosclerosis</i> , 2006, 184, 283-289.	0.4	18
25	Nanoformulated copper/zinc superoxide dismutase attenuates vascular cell activation and aortic inflammation in obesity. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 495-500.	1.0	17
26	Role of apathy in the effectiveness of weight management programmes. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 419-423.	2.2	16
27	Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. <i>Vascular Pharmacology</i> , 2007, 46, 188-194.	1.0	13
28	Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2426-2434.	2.2	11
29	Islet Autoimmunity Is Highly Prevalent and Associated With Diminished β -Cell Function in Patients With Type 2 Diabetes in the GRADE Study. <i>Diabetes</i> , 2022, 71, 1261-1271.	0.3	11
30	The impact of type 1 diabetes on neural activity serving attention. <i>Human Brain Mapping</i> , 2019, 40, 1093-1100.	1.9	10
31	A combination of Omega-3 PUFAs and COX inhibitors: A novel strategy to manage obesity-linked dyslipidemia and adipose tissue inflammation. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107494.	1.2	10
32	Myristic Acid Supplementation Aggravates High Fat Diet-Induced Adipose Inflammation and Systemic Insulin Resistance in Mice. <i>Biomolecules</i> , 2022, 12, 739.	1.8	10
33	Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells. <i>Vascular Pharmacology</i> , 2009, 51, 162-168.	1.0	9
34	Adrenal Insufficiency From Immune Checkpoint Inhibitors Masquerading as Sepsis. <i>JCO Oncology Practice</i> , 2021, 17, 212-214.	1.4	7
35	Hematopoietic cyclooxygenase-2 deficiency increases adipose tissue inflammation and adiposity in obesity. <i>Obesity</i> , 2015, 23, 2037-2045.	1.5	6
36	The effect of group clinics in the control of diabetes. <i>Primary Care Diabetes</i> , 2010, 4, 251-254.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Altered motor dynamics in type 1 diabetes modulate behavioral performance. <i>NeuroImage: Clinical</i> , 2019, 24, 101977.	1.4	5
38	Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2009, 2, 165.	1.1	5
39	A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice. <i>Journal of Nutritional Biochemistry</i> , 2017, 42, 149-159.	1.9	4
40	Quantifying vehicle control from physiology in type 1 diabetes. <i>Traffic Injury Prevention</i> , 2019, 20, S26-S31.	0.6	4
41	KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease. <i>Kidney International</i> , 2022, 101, 420.	2.6	4
42	A retrospective review of insulin requirements in patients using U-500 insulin hospitalized to a Veterans Affairs Hospital. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 874-879.	1.2	3
43	Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs). <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001830.	1.2	3
44	At-Risk Driving Behavior in Drivers with Diabetes: A Neuroergonomics Approach. <i>Proceedings of the Human Factors and Ergonomics Society</i> , 2017, 61, 1881-1885.	0.2	1
45	Implications of the CANVAS Study in Reducing Cardiovascular Outcomes. <i>Current Diabetes Reports</i> , 2018, 18, 142.	1.7	1
46	SAT-347 Diagnosis of Autosomal Dominant Hypocalcemia Type 1 Following the Initiation of Imatinib for Treatment of Chronic Myeloid Leukemia. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	1
47	Does pioglitazone reduce carotid intima-media thickness in patients with type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 394-395.	2.9	0
48	The Effectiveness of Adding Pharmacotherapy to Dietary Counseling for Veterans in a Veterans Health Administration Move! Weight Management Program. <i>Journal of the Endocrine Society</i> , 2021, 5, A38-A38.	0.1	0
49	Testing the Psychometric Characteristics of the Revised Mastery of Stress Instrument in Adults With Type 2 Diabetes. <i>Journal of Nursing Measurement</i> , 2021, , JNM-D-20-00137.	0.2	0
50	CARDIAC RYANODINE RECEPTOR ACQUIRES A GAIN OF FUNCTION PHENOTYPE DURING TYPE 1 DIABETES. <i>FASEB Journal</i> , 2011, 25, 1112.13.	0.2	0
51	Abstract 213: Differential Effects of Nanoformulated Copper/zinc Superoxide Dismutase in Regulating Fasting Blood Glucose Levels in Mice Fed a Low versus High Fat Diet. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, .	1.1	0
52	The effect of nonpharmaceutical weight loss interventions in rural patients with diabetes: REPOWER Diabetes. <i>Obesity</i> , 2022, 30, 884-892.	1.5	0
53	Differential impact of glycemic control and comorbid conditions on the neurophysiology underlying task switching in older adults with type 2 diabetes. <i>Aging</i> , 0, , .	1.4	0